Study status
The trial will be initiated June 2023. The plan is to recruit 100 patients in 18 months. It is estimated that each patient will receive treatment for an average of approximately 5 months and additional follow-up after the accrual interval will be 6 months. The entire study is thus projected to be concluded within 2 years.